161 related articles for article (PubMed ID: 34793609)
1. Setting up clinical trials for success: Applying preclinical advances in combined TGFβ/PD-L1 inhibition to ongoing clinical studies.
Strait AA; Wang XJ
Mol Carcinog; 2022 Feb; 61(2):239-242. PubMed ID: 34793609
[TBL] [Abstract][Full Text] [Related]
2. Preclinical and clinical studies of bintrafusp alfa, a novel bifunctional anti-PD-L1/TGFβRII agent: Current status.
Gameiro SR; Strauss J; Gulley JL; Schlom J
Exp Biol Med (Maywood); 2022 Jul; 247(13):1124-1134. PubMed ID: 35473390
[TBL] [Abstract][Full Text] [Related]
3. Distinct immune microenvironment profiles of therapeutic responders emerge in combined TGFβ/PD-L1 blockade-treated squamous cell carcinoma.
Strait AA; Woolaver RA; Hall SC; Young CD; Karam SD; Jimeno A; Lan Y; Raben D; Wang JH; Wang XJ
Commun Biol; 2021 Aug; 4(1):1005. PubMed ID: 34433873
[TBL] [Abstract][Full Text] [Related]
4. Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances.
Lind H; Gameiro SR; Jochems C; Donahue RN; Strauss J; Gulley JL; Palena C; Schlom J
J Immunother Cancer; 2020 Feb; 8(1):. PubMed ID: 32079617
[TBL] [Abstract][Full Text] [Related]
5. Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Patients with Esophageal Squamous Cell Carcinoma: Results from a Phase 1 Cohort in Asia.
Lin CC; Doi T; Muro K; Hou MM; Esaki T; Hara H; Chung HC; Helwig C; Dussault I; Osada M; Kondo S
Target Oncol; 2021 Jul; 16(4):447-459. PubMed ID: 33840050
[TBL] [Abstract][Full Text] [Related]
6. Next-generation immunotherapy for solid tumors: combination immunotherapy with crosstalk blockade of TGFβ and PD-1/PD-L1.
Quach HT; Hou Z; Bellis RY; Saini JK; Amador-Molina A; Adusumilli PS; Xiong Y
Expert Opin Investig Drugs; 2022 Nov; 31(11):1187-1202. PubMed ID: 36448335
[TBL] [Abstract][Full Text] [Related]
7. DNA-PK Inhibitor Peposertib Amplifies Radiation-Induced Inflammatory Micronucleation and Enhances TGFβ/PD-L1 Targeted Cancer Immunotherapy.
Carr MI; Chiu LY; Guo Y; Xu C; Lazorchak AS; Yu H; Qin G; Qi J; Marelli B; Lan Y; Sun Q; Czauderna F; Zenke FT; Blaukat A; Vassilev LT
Mol Cancer Res; 2022 Apr; 20(4):568-582. PubMed ID: 34980594
[TBL] [Abstract][Full Text] [Related]
8. Moving beyond the T cell synapse for combination neoadjuvant immunotherapy in head and neck cancer.
Bell RB; Gough M; Crittenden M; Young K
J Clin Invest; 2022 Sep; 132(18):. PubMed ID: 36106641
[TBL] [Abstract][Full Text] [Related]
9. Colocalized targeting of TGF-β and PD-L1 by bintrafusp alfa elicits distinct antitumor responses.
Lan Y; Yeung TL; Huang H; Wegener AA; Saha S; Toister-Achituv M; Jenkins MH; Chiu LY; Lazorchak A; Tarcic O; Wang H; Qi J; Locke G; Kalimi D; Qin G; Marelli B; Yu H; Gross AW; Derner MG; Soloviev M; Botte M; Sircar A; Ma H; Sood VD; Zhang D; Jiang F; Lo KM
J Immunother Cancer; 2022 Jul; 10(7):. PubMed ID: 35858707
[TBL] [Abstract][Full Text] [Related]
10. Radiolabelling and preclinical characterization of
Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
[TBL] [Abstract][Full Text] [Related]
11. Selection of the Recommended Phase 2 Dose for Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1.
Vugmeyster Y; Wilkins J; Koenig A; El Bawab S; Dussault I; Ojalvo LS; De Banerjee S; Klopp-Schulze L; Khandelwal A
Clin Pharmacol Ther; 2020 Sep; 108(3):566-574. PubMed ID: 31955412
[TBL] [Abstract][Full Text] [Related]
12. Safety and Tolerability of Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGFβ and PD-L1, in Asian Patients with Pretreated Recurrent or Refractory Gastric Cancer.
Kang YK; Bang YJ; Kondo S; Chung HC; Muro K; Dussault I; Helwig C; Osada M; Doi T
Clin Cancer Res; 2020 Jul; 26(13):3202-3210. PubMed ID: 32299818
[TBL] [Abstract][Full Text] [Related]
13. TGFβ-Directed Therapeutics: 2020.
Teicher BA
Pharmacol Ther; 2021 Jan; 217():107666. PubMed ID: 32835827
[TBL] [Abstract][Full Text] [Related]
14. Dual inhibition of TGF-β and PD-L1: a novel approach to cancer treatment.
Gulley JL; Schlom J; Barcellos-Hoff MH; Wang XJ; Seoane J; Audhuy F; Lan Y; Dussault I; Moustakas A
Mol Oncol; 2022 Jun; 16(11):2117-2134. PubMed ID: 34854206
[TBL] [Abstract][Full Text] [Related]
15. Bintrafusp Alfa: A Bifunctional Fusion Protein Targeting PD-L1 and TGF-β, in Patients with Pretreated Colorectal Cancer: Results from a Phase I Trial.
Spira A; Wertheim MS; Kim EJ; Tan B; Lenz HJ; Nikolinakos P; Rich PL; Jehl G; Machl A; Ito R; Gulley JL; Kopetz S
Oncologist; 2023 Feb; 28(2):e124-e127. PubMed ID: 36576431
[TBL] [Abstract][Full Text] [Related]
16. Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1.
Vugmeyster Y; Grisic AM; Wilkins JJ; Loos AH; Hallwachs R; Osada M; Venkatakrishnan K; Khandelwal A
Cancer Chemother Pharmacol; 2022 Oct; 90(4):369-379. PubMed ID: 36066618
[TBL] [Abstract][Full Text] [Related]
17. Immune targeting of three independent suppressive pathways (TIGIT, PD-L1, TGFβ) provides significant antitumor efficacy in immune checkpoint resistant models.
Franks SE; Fabian KP; Santiago-Sánchez G; Wolfson B; Hodge JW
Oncoimmunology; 2022; 11(1):2124666. PubMed ID: 36211806
[TBL] [Abstract][Full Text] [Related]
18. Analysis of the tumor microenvironment and anti-tumor efficacy of subcutaneous vs systemic delivery of the bifunctional agent bintrafusp alfa.
Ozawa Y; Hicks KC; Minnar CM; Knudson KM; Schlom J; Gameiro SR
Oncoimmunology; 2021 May; 10(1):1915561. PubMed ID: 33996267
[TBL] [Abstract][Full Text] [Related]
19. Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in patients with human papillomavirus-associated malignancies.
Strauss J; Gatti-Mays ME; Cho BC; Hill A; Salas S; McClay E; Redman JM; Sater HA; Donahue RN; Jochems C; Lamping E; Burmeister A; Marté JL; Cordes LM; Bilusic M; Karzai F; Ojalvo LS; Jehl G; Rolfe PA; Hinrichs CS; Madan RA; Schlom J; Gulley JL
J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33323462
[TBL] [Abstract][Full Text] [Related]
20. Stromal Fibroblasts Mediate Anti-PD-1 Resistance via MMP-9 and Dictate TGFβ Inhibitor Sequencing in Melanoma.
Zhao F; Evans K; Xiao C; DeVito N; Theivanthiran B; Holtzhausen A; Siska PJ; Blobe GC; Hanks BA
Cancer Immunol Res; 2018 Dec; 6(12):1459-1471. PubMed ID: 30209062
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
